UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET
Company Participants
Vincent Perrone - Senior Director of IR
Liz Barrett - President and CEO
Mark Schoenberg - Chief Medical Officer
Jeff Bova - Chief Commercial Officer
Don Kim - CFO
Conference Call Participants
Ram Selvaraju - H.C. Wainwright
Boris Peaker - Cowen
Chris Howerton - Jefferies
Matt Kaplan - Ladenburg Thalmann
Leland Gershell - Oppenheimer
Anita Dushyanth - Berenberg Capital
Operator
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to UroGen Pharma's First Quarter 2022 Financial Results and Business Update Conference Call.
It is now my pleasure to turn the call over to Vincent Perrone, Senior Director of Investor Relations for UroGen Pharma. Please go ahead.
Vincent Perrone
Thank you, operator. Good morning everyone and welcome to UroGen Pharma's first quarter 2022 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended March 31, 2021. The press release can be accessed on the Investors portion of our website at investors.urogen.com.
Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, Chief Commercial Officer; and Don Kim, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities relating to Jelmyto ongoing and planned clinical trials, commercial and clinical milestones in the year ahead. The potential of UGN-102 to transform the treatment paradigm as the first viable nonsurgical alternative for low-grade intermediate risk NMIBC, potential future commercialization activities for UGN-102, if approved, data presentations, regulatory filings, future research and development efforts, our goals, potentially reaching cash flow breakeven by 2025 and 2022 financial guidance, among other things.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents, including under the risk factors heading of our quarterly report on Form 10-Q for the quarter ended March 31, 2022, filed today.
You are cautioned not to place undue reliance on these forward-looking statements, and UroGen disclaims any obligation to update these statements.
I will now turn the call over to Liz. Liz?
Liz Barrett
Thank you, Vincent. And thank you everyone joining us today.